What's up guys and welcome back to the
channel, it's been a few weeks since I
last posted any videos but today I have
a special video talking about some very
good opportunities right now in biotech.
Both pharma and biotech have been having
a great month overall but each of these
has serious upside potential in both the
short and medium terms so before we get
into it if you like the content help me
grow this channel smash the like button
and drop me a comment small channels
like this only grow up the videos are
getting likes and comments so let me
know what you think of each of these
stocks I would really appreciate if you
could help me get to 300 likes on this
video let's make it happen subscribe to
the channel if you're new and hit the
bell notification so you never miss a
video with potential to make you money.
I want to point out that i'm not a
financial advisor and this is not
financial advice now let's get into it.
T2 biosystems this stock has traded on
nasdaq ticker tto
now this stock has already gained over
40 percent in the past week but tt00
stock
is still down about 80 since august 2021
T2 Biosystems (ttoo stock) is a massachusetts-based
company developing diagnostic products
targeting sepsis hemostatis bacteria and
lyme disease the company was founded in
2006.
T2 Biosystems (ttoo stock) titled themselves as an
emerging leader in the field of in-vitro
diagnostics dedicated to saving lives
and reducing the cost of healthcare by
providing t2 magnetic resonance
technology that enables detection of
pathogens biomarkers and other
abnormalities in various patient samples
such as blood samples
the company offers its main product
which is the t2dx
instrument this instrument is a fully
automated walk-away clinical multiplex
bench top diagnostic system capable of
running tests directly from whole blood
basically this machine is used to
identify fungi or bacteria in the
bloodstream
quickly and this stock has been gaining
a lot of attention lately this is one of
the most traded stocks in the world over
the past week due to recent news which i
will look at in a moment
but what do analysts think of ttoo stock
the stock hit its all-time low earlier
this month at just 11 cents
and as we can see here from market beat
the average analyst price target is 1.10
which is over 400 percent above the
current price
price targets last year were generally
in the 3 to 3.50 range so this stock
still has a lot of upside scope
and over the past week we can see here
that the trading volume has gone insane
for t2 biosystem stock
being the world's most traded stock on
august 11th
which seen ttoo go from 11 cents up to
30 cents in less than 48 hours
and that has a lot to do with this
T2 Biosystems (ttoo stock)
is set to explore the potential to
develop a diagnostic test for monkeypox virus
(Is T2 Biosystems stock a buy or a sell?)
on august 4th
monkey pox was declared a public health
emergency a move that is expected to
free up additional funding and tools to
fight the disease
so any news from t2 regarding this test
should have a positive impact on the
share price going forward
T2 Biosystems (ttoo stock) are due to release their
latest earnings report on monday but
looking at the most recent earnings we
can see that they have assets of 49
million and negative equity of 25
million so this is not a good balance
sheet but the majority of the
liabilities is made up of notes payable
the current ratio here is nearly three
to one so it's not as bad as first seems
but considering that the company is
making
orderly losses in excess of 16 million
dollars it is likely that they will need
to raise cash
within the next year. next up we have
VERU (Nasdaq: VERU)
this stock is traded on the nasdaq the
ticker is v e r u
now vero stock has already gained over
50 in the past week and is up
over 200 percent in six months when i
first spoke about this stock last year
it was only seven dollars
so with the current share price at
nearly twenty dollars it shows just how
far they have come over the past year
beeru is a biopharma company with an
oncology focus the company's strategy is
primarily to focus on the clinical
development and commercialization of
oncology drugs for the management of two
of the most prevalent
cancers in the world prostate cancer and
breast cancer as well as the strategy
for developing and launching high value
biopharmaceutical products for prostate
and breast cancers beeru also plans to
continue to grow its sexual health
business to invest proceeds in the
clinical development of the drug
pipeline
to access large premium oncology markets
but the exciting side of the business
from an investor's point of view right
now
is that vero have an impressive pipeline
not just for prostate cancer and breast
cancer
but they are also testing a cova
treatment for its stroke
it's a visaboon
formerly known as VERU (Nasdaq: VERU)
111
VERU (Nasdaq: VERU) has got a lot of attention in the
past couple of days
as we can see here with 59 million
shares traded on august 11th
largely thanks to potential upside from
prospective emergency use approvals for
its covert 19 treatment
but what do analysts think of VERU (Nasdaq: VERU)
five wall street analysts have set 12
month price targets for vero in the last
three months the average price target is
30
with a high forecast of 36 and a low of
24. this average price represents a 58
upside from the last price
looking at market beat we can see the
vero is currently on the uptrend and the
stock is at its highest point since 2021
with the stock being at the top of not
only the daily range but the 50-day and
the 52-week range also
and we can see here that all recent
analyst reports are rating vero as a buy
with a price target of at least 30
dollars
looking at the company's most recent
quarterly earnings report we can see
that they have total assets of 160
million and liabilities of just 43
million giving viru an asset to
liability ratio of about four to one and
100 million of this is in cash which is
very significant too in giving this a
very strong balance sheet
but the company is making significant
losses as we can see here from the
income statement with with losses of
over 22 million dollars for the quarter
so guys what did you think of these
first two stocks you may already have
been aware of these companies if you've
been following my channel
but drop a comment and let me know what
you think future holds for these stocks
and don't forget to hit the like button
and subscribe to the channel if you're
new #stocks #veru #ttoo
Next up we have bionano genomics
this stock is traded on the nasdaq with
the BNGO ticker
now this stock has already gained over
100 in the past month and is now at an
eight month high
but it is still about 75 down
from the stocks 2021
high of over 15 dollars
Bionano Genomics (bngo stock) is a provider of genome
analysis solutions that can enable
researchers and clinicians to reveal
answers to challenging questions in
biology and medicine the company's
mission is to transform the way the
world sees the genome through ogm
solutions diagnostic services and
software
ogm stands for optical genome mapping
and the company
offers ogm solutions for applications
across basic
translational and clinical research
bionano (bngo stock) also provides diagnostic testing
for patients with
clinical presentations consistent with
autism spectrum disorder and other newer
developmental
disabilities
the company also offers industry-leading
software solutions which integrate next
generation sequencing to provide
analysis visualization interpretation
across the genome in one
consolidated view
bionano genomics offers the sapphire
system that uses ogm to conduct genome
analysis and understand genetic
variation and function
as I said a moment ago
BNGO stock has gained over 100 in
the past month and that is part
due to plenty of good news recently
this week bionnano announced first
publication using ogm for detection of
repeat expansions in canvas and adult
onset ataxia
the study noted the successful use of
ogm to replace the labor-intensive and
time-consuming southern bloc
which has been the gold standard for
sizing repeat expansions up until now
and management are very optimistic for
the future but what do wall street
analysts think of bngo stock
looking at marketbeat we can see the
bngo has recovered well in the past 50
days but it is still in the lower half
of its 52-week range remember that this
stock did trade as high as 15 in the
past while the average analyst price
target is ten dollars now so there is
clear upside here
the most recent of these targets was set
by openheimer
just last month rating this as
outperform or buy and a price target of
dollars which is still over two hundred
percent upside
bngo is backed by several large
institutions with ownership of over 26
percent and during the previous two
years 167 institutional investors in
hedge funds health shares of bngo stock
looking at the most recent financial
statements released last week we can see
that the company
had total assets of over 300 million
dollars and total liabilities of just
36.
revenue has increased year over year
but losses for the first six months of
the year add to over 60 million dollars
so the company still has a long way to
go before becoming profitable.
and then we have Ocugen (OCGN stock) again traded on
nasdaq with the ticker ocg in
Ocugen (OCGN stock) is only beginning to pop right
now having gained 15 percent in the past
three weeks
but the stock is still about 85 percent
below its 2021 highs
Ocugen (OCGN stock) is focused on discovering
developing and commercializing
novel gene therapies
biologicals and vaccines
that improve health and offer hope for
people with global communities one of
Ocugen (OCGN stock)'s main focus areas is finding
innovation that will make hard to treat
blindness disease a thing of the past
using innovation to take science in new
directions
their breakthrough modifier gene therapy
platform has the potential to treat
multiple diseases with one drug and they
are advancing research in other
therapeutic areas to offer new options
for people with unmet medical needs
Ocugen (OCGN stock) have a number of programs at
various stages in their pipeline their
leading drug is kovacsen but they also
have neocart ocu-400
ocu-410 and ocu-200 which are at various
stages of testing
now one of the reasons for the sharp
drop in stock price over recent months
is that the fda had placed a clinical
hold on kovacsen and this is likely to
take another year at least before we see
any movement on this
so for now the best drug candidates
could well be neocart
for repairing knee cartilage
and ocu-400 which has the potential to
be effective in restoring retinal
integrity
and function across a range of
genetically diverse inherited retinal
diseases
but what do analysts think of ocg in
stock
looking at market beat we can see that
Ocugen (OCGN stock) has recovered well in the past 50
days but it is still very low on the
52-week range
remember that this stock did trade as
high as 17 less than one year ago while
the average analyst price target is 780.
so there is clear upside here and
trading volume is still low now at only
5 million shares on friday
the most recent price target was set by
roth capital
rating this stock as a buy
and a price target of eight dollars
Ocugen (OCGN stock) is backed by several large
institutions with ownership of nearly 40
percent and during the previous two
years 119 institutional investors and
hedge funds have held shares of ocg in
stock
looking at the most recent financial
statements we can see that the company
has total assets
of over 130 million and total
liabilities of just 15 million
so they have an asset to liability ratio
of greater than 10 to 1 and cash of 115
million so this is a very strong balance
sheet
but this is still a pre-revenue stage
company and losses for the first six
months of the year are over 37 million
dollars so the company still has a long
way to go
before I give you a quick conclusion
what do you think of these stocks and
which one do you think has the most
upside potential drop a comment and let
me know what you think
and remember
to smash the like button and subscribe
to the channel if you're new
so from my conclusion
i think that each of these stocks have
their own unique potential and offer a
lot of future upside for t2 biosystem
monday will be a big trading day because
they released their latest earnings
report but really the diagnostic test
from monkey pox will prove to be the big
driver in the coming months and there
will be a lot of money invested around
the world to try and prevent this from
becoming another pandemic this is the
stock that you need to have on your
watch list for Ocugen (OCGN stock)
i think that this is yet to make any
real move and I expect to see some
short-term movement which will offer
some nice gains but in the long term
they need to get fda approval soon
as for bngo and VERU (Nasdaq: VERU)
these have been making huge gains
recently bngo is still far below its
2021 high point
while I expect a little pullback soon
for VERU (Nasdaq: VERU) given that it is near its
all-time highs but then I expect this to
continue upwards remember guys that i'm
not a financial advisor
and that this is just my opinion and not
financial advice
this is the reason that I have looked at
analyst price targets for all of these
stocks they are the professionals and
they are given huge targets to each one
of these stocks
if you enjoyed this video like and
subscribe follow me on twitter and i'll
catch you in the next update